The question for 2026 is whether the reset is working. Half-year results on 15 July 2026 showed the operating loss cut by 72%, cash runway into Q2 2027 and a reiterated target of at least £2.1m ofRevenuethis year. But the board also disclosed a …
The question is whether a still loss-making business can convert that momentum into the higher-marginRoyaltystreams management has promised before the cash raised in April 2026 runs down. With in vivo radiopharmaceutical data due by the end of 2026 and a new joint broker appointed, …
The deal lands a week after interim results showing Shield's first operating profit, and a month after the shares hit a 52-week low of 3.70p. With the stock at around 6p and aMarket Valueof roughly £64m, the question is whether aBusinessgenerating $30m of half-year …
The underlying business, which sells foot-care products through Boots, Superdrug and the NHS, AxisBiotix gut-skin supplements and contractManufacturingservices, grew revenue by 37% in the first half of its financial year. The question is whether that operational story can now be separated from the governance …
The key question is whether the NHS, after restructuring that management has called the toughest trading conditions it has known, finally converts years of pilots into a contract of scale — and whether Feedback's cash, guided to last only to mid-2027, holds out long …
The question is whether these wins, together with a first NHS clinical trial for WellBiome and the long-awaited demonstration of its SweetBiotix sugar substitute, can move a business that still lost £3.9m before tax in 2025 on revenue of £1.2m, and whose runway has …
For a company until recently almost synonymous with human challenge trials, the shift to a broader clinical development platform is the key question. With the shares at roughly 8.4p and aMarket Capitalisationnear £58m, according to lse.co.uk on 2 September 2026, the market values hVIVO …
The key question is timing. Avacta said in May 2026 that its cash runway stretches only into early Q1 2027, and its accounts flag a material uncertainty over going concern. With first AVA6103 data promised for late 2026 and partnering talks unsigned, the gap …
Yet the newsflow has not been uniformly bleak. On 28 August 2026 the company published real-world results from an 18-month pilot of its CARDIO inCode-Score polygenic risk test in Catalonia, presented at the European Society of Cardiology Congress in Munich. With a fresh USFood …
The question is whether that commercial momentum can outrun the balance sheet. The FY25 accounts, published on 29 June 2026, carry a material uncertainty over going concern: the directors say further funding is needed before the end of 2026, even after a £2.6mEquityraise at …